The MediBeacon system uses an optical skin sensor combined with a proprietary agent that glows in the presence of light. The goal is to provide clinicians continuous real-time monitoring of kidney function. MediBeacon has completed clinical studies in healthy and impaired subjects.
The tracer agent and monitor are not yet approved for sale.
The Clinical Need
Real-time point of care measurement of renal function will improve patient outcomes in the ICU and the operating suite and achieve optimal dosing strategies for nephrotoxic drug interventions such as chemotherapeutics and imaging contrast agents.
Current Clinical Practice
Current clinical practice for determining renal function is measurement of creatinine in the patient’s blood serum. Serum creatinine concentration rises post kidney insult, however, there are several issues that make this practice much less than optimal.